Patents by Inventor Roy H. L. Pang
Roy H. L. Pang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220242947Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.Type: ApplicationFiled: September 19, 2019Publication date: August 4, 2022Inventors: William G. North, Roy H.L. Pang
-
Patent number: 10407504Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.Type: GrantFiled: October 12, 2016Date of Patent: September 10, 2019Assignee: Woomera TherapeuticsInventors: William G. North, Roy H. L. Pang
-
Patent number: 10155810Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.Type: GrantFiled: October 10, 2016Date of Patent: December 18, 2018Assignee: Woomera TherapeuticsInventors: William G. North, Roy H. L. Pang
-
Publication number: 20170107283Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.Type: ApplicationFiled: October 10, 2016Publication date: April 20, 2017Inventors: William G. North, Roy H.L. Pang
-
Publication number: 20170107292Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.Type: ApplicationFiled: October 12, 2016Publication date: April 20, 2017Inventors: William G. North, Roy H.L. Pang
-
Publication number: 20140341802Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: Woomera TherapeuticsInventors: William G. North, Roy H.L. Pang
-
Publication number: 20140341810Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: WOOMERA THERAPEUTICSInventors: William G. North, Roy H.L. Pang
-
Patent number: 7557078Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: September 25, 1997Date of Patent: July 7, 2009Assignee: Stryker CorporationInventors: David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Engin Ozkaynak, Roy H. L. Pang, Charles M. Cohen
-
Publication number: 20080233170Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: ApplicationFiled: February 27, 2008Publication date: September 25, 2008Applicant: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 7196056Abstract: Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.Type: GrantFiled: March 10, 2003Date of Patent: March 27, 2007Assignee: Curis, Inc.Inventors: Charles M. Cohen, Kuber T. Sampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
-
Patent number: 7176284Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: May 2, 2003Date of Patent: February 13, 2007Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 7060680Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: January 15, 2002Date of Patent: June 13, 2006Assignee: Curis, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 7056882Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: GrantFiled: September 13, 2001Date of Patent: June 6, 2006Assignee: Curis, Inc.Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
-
Publication number: 20060116507Abstract: A method and system for controlling the provisioning of a device with information for accessing services of a wireless service provider via a wireless network is provided. The provisioning system initially stores automatic provisioning information on the device that includes the identification of wireless service providers that have the capability to automatically provision the device. When a user of the device wants to subscribe to a service of a service provider, the provisioning system requests an automatic provisioning service of the service provider to provide information describing available services and information needed to subscribe to those services. When the user selects a service and provides the needed information, the provisioning system retrieves provisioning information for the selected service from the service provider. The provisioning system stores the provisioning information on the device so that the device can then be used to access the selected service of the service provider.Type: ApplicationFiled: October 24, 1997Publication date: June 1, 2006Inventors: HERMANN OPPERMANN, ENGIN OZKAYNAK, THANGAVEL KUBERASAMPATH, DAVID C. RUEGER, ROY H. L. PANG
-
Publication number: 20050255141Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: ApplicationFiled: February 4, 2005Publication date: November 17, 2005Applicant: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David Rueger, Roy H. L. Pang
-
Patent number: 6919308Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: GrantFiled: December 17, 2002Date of Patent: July 19, 2005Assignee: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 6800603Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: June 16, 1994Date of Patent: October 5, 2004Assignee: Curis, Inc.Inventors: David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
-
Publication number: 20040102373Abstract: Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.Type: ApplicationFiled: March 10, 2003Publication date: May 27, 2004Applicant: Curis, Inc.Inventors: Charles M. Cohen, Kuber T. Sampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
-
Publication number: 20040077546Abstract: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.Type: ApplicationFiled: May 2, 2003Publication date: April 22, 2004Applicant: Stryker CorporationInventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang
-
Patent number: 6723698Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.Type: GrantFiled: September 25, 1997Date of Patent: April 20, 2004Assignee: Curis, Inc.Inventors: David C. Rueger, Kuber T. Sampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen